Avelumab regulatory update

FDA granted Fast Track designation to avelumab from Merck to treat metastatic Merkel cell carcinoma (MCC). The human IgG1 mAb against PD-L1 is in the Phase II JAVELIN Merkel 200 trial to treat metas...